Spago Nanomedical AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
For the nine months, sales was SEK 3.15 million compared to SEK 3.6 million a year ago. Revenue was SEK 4.45 million compared to SEK 4.77 million a year ago. Net loss was SEK 28.04 million compared to SEK 27.78 million a year ago. Basic loss per share from continuing operations was SEK 0.51 compared to SEK 0.67 a year ago. Diluted loss per share from continuing operations was SEK 0.51 compared to SEK 0.67 a year ago.